We are live on ! Find out more
BBOT

BridgeBio Oncology
BBOT

32 hedge funds and large institutions have $173M invested in BridgeBio Oncology in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

3% more funds holding

Funds holding: 31 → 32 (+1)

1% more capital invested

Capital invested by funds: $171M → $173M (+$1.58M)

0.38% more ownership

Funds ownership: 86.59% → 86.97% (+0.38%)

Holders
32
Holders Change
+1
Holders Change %
+3.23%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$521K
2
UBS Group
UBS Group
Switzerland
+$368K
3
Millennium Management
Millennium Management
New York
+$126K
4
Citadel Advisors
Citadel Advisors
Florida
+$73.9K
5
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$27.3K

Top Sellers

Rank Fund Capital Flow
1
SSA
Schonfeld Strategic Advisors
New York
-$1.25M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$419K
3
BlackRock
BlackRock
New York
-$11.9K
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$842
5
JP Morgan Chase
JP Morgan Chase
New York
-$42
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$30.5M – – –
BlackRock
2
BlackRock
New York
$15.7M -$11.9K -1,135 -0.1%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$14.7M – – –
Citadel Advisors
4
Citadel Advisors
Florida
$14.1M +$73.9K +7,020 +0.5%
Millennium Management
5
Millennium Management
New York
$12M +$126K +11,985 +1%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$11.4M -$419K -39,827 -4%
SC
7
Sculptor Capital
New York
$7.4M – – –
FCM
8
Farallon Capital Management
California
$6.3M – – –
SCM
9
Silverarc Capital Management
Massachusetts
$5.39M – – –
CC
10
Commodore Capital
New York
$5.25M – – –
GPP
11
Great Point Partners
Connecticut
$5.25M – – –
PA
12
Perceptive Advisors
New York
$5.25M – – –
SFM
13
Soros Fund Management
New York
$4.99M +$1.2K +114 +0%
ACM
14
ADAR1 Capital Management
Texas
$4.24M – – –
T. Rowe Price Investment Management
15
T. Rowe Price Investment Management
Maryland
$4.2M +$27.3K +2,598 +0.7%
LCM
16
Laurion Capital Management
New York
$3.15M – – –
HCI
17
Harraden Circle Investments
New York
$2.7M +$2.71M +257,226 New
AAA
18
Affinity Asset Advisors
New York
$2.63M – – –
OCA
19
Octagon Capital Advisors
New York
$2.63M – – –
SC
20
Stempoint Capital
New York
$2.11M +$9.47K +900 +0.5%
Two Sigma Investments
21
Two Sigma Investments
New York
$1.99M – – –
DAM
22
Decagon Asset Management
United Kingdom
$1.96M +$1.96M +186,454 New
Wellington Management Group
23
Wellington Management Group
Massachusetts
$1.94M -$842 -80 -0%
ACP
24
Acuta Capital Partners
California
$1.9M – – –
TD Asset Management
25
TD Asset Management
Ontario, Canada
$1.52M – – –
1
2

BBOT Hedge Fund Activity: Q4 2024 in Review

32 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q4 2024, worth a combined $173M — up 0.92% from $171M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BBOT positions and 3 closed out — a net gain of 2 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $521K. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $1.25M sold.

  • 32 institutional investors held BridgeBio Oncology (BBOT) as of Q4 2024, up from 31 in Q3 2024.
  • Funds reported $173M of BridgeBio Oncology stock for Q4 2024, up 0.92% quarter-over-quarter.
  • 5 funds opened new BridgeBio Oncology positions in Q4 2024 and 3 closed out, a net change of +2 holders.
  • The largest BridgeBio Oncology buyer in Q4 2024 was Toronto Dominion Bank, an estimated $521K added.
  • The largest BridgeBio Oncology seller in Q4 2024 was Schonfeld Strategic Advisors, an estimated $1.25M sold.

Based on aggregated 13F filings for Q4 2024.